Cargando…

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus

BACKGROUND: Deteriorated arterial function and high incidence of cardiovascular events characterise diabetes mellitus. Metformin and recent antidiabetic drugs, SGLT2 inhibitors, reduce cardiovascular events. We explored the possible effects of empagliflozin’s effect on top of metformin treatment on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lunder, Mojca, Janić, Miodrag, Japelj, Miha, Juretič, Andrej, Janež, Andrej, Šabovič, Mišo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276165/ https://www.ncbi.nlm.nih.gov/pubmed/30509271 http://dx.doi.org/10.1186/s12933-018-0797-6

Ejemplares similares

Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes
por: Janić, Miodrag, et al.
Publicado: (2022)

Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
por: Lunder, Mojca, et al.
Publicado: (2021)

Arterial Stiffness and Cardiovascular Therapy
por: Janić, Miodrag, et al.
Publicado: (2014)

A Low-Dose Combination of Fluvastatin and Valsartan: A New “Drug” and a New Approach for Decreasing the Arterial Age
por: Janić, Miodrag, et al.
Publicado: (2015)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Associations among different functional and structural arterial wall properties and their relations to traditional cardiovascular risk factors in healthy subjects: a cross-sectional study
por: Lunder, Mojca, et al.
Publicado: (2012)

A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts
por: Lunder, Mojca, et al.
Publicado: (2012)

Coenzyme Q10 Supplementation Decreases Statin-Related Mild-to-Moderate Muscle Symptoms: A Randomized Clinical Study
por: Skarlovnik, Ajda, et al.
Publicado: (2014)

Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat “Aging-Related Disorders”
por: Janić, Miodrag, et al.
Publicado: (2019)

Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience
por: Janić, Miodrag, et al.
Publicado: (2023)

Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients
por: Nikolajević Starčević, Jovana, et al.
Publicado: (2019)

Health-Related Quality of Life Assessment in Older Patients with Type 1 and Type 2 Diabetes
por: Volčanšek, Špela, et al.
Publicado: (2023)

The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
por: Navodnik, Maja Preložnik, et al.
Publicado: (2023)

The preventive cardiovascular effect of a combination of statin and angiotensin receptor blocker at sub-therapeutic doses in middle-aged healthy volunteers
por: Šinigoj, Petra, et al.
Publicado: (2009)

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
por: Cherney, David ZI, et al.
Publicado: (2014)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
por: Bosch, Agnes, et al.
Publicado: (2019)

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
por: Jensterle Sever, Mojca, et al.
Publicado: (2014)

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time
por: Merzel Šabović, Eva Klara, et al.
Publicado: (2022)

Inflammatory, Metabolic, and Coagulation Effects on Medial Arterial Calcification in Patients with Peripheral Arterial Disease
por: Nikolajević, Jovana, et al.
Publicado: (2023)

Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study
por: Kravos, Nika Aleksandra, et al.
Publicado: (2021)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport
por: Herman, Rok, et al.
Publicado: (2022)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
por: Jensterle, Mojca, et al.
Publicado: (2019)

Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
por: Irace, Concetta, et al.
Publicado: (2018)

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
por: Shimizu, Wataru, et al.
Publicado: (2020)

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
por: Jensterle, Mojca, et al.
Publicado: (2015)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment
por: Klen, Jasna, et al.
Publicado: (2014)

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
por: Jensterle, Mojca, et al.
Publicado: (2022)

The Role of Physicians’ Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus
por: Janež, Andrej, et al.
Publicado: (2022)

Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
por: Li, Tian, et al.
Publicado: (2021)

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
por: Sarak, Bradley, et al.
Publicado: (2021)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
por: Gaborit, B., et al.
Publicado: (2021)

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
por: Daud, Elias, et al.
Publicado: (2021)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tjg8udt6ceincpefok9lni0r3t